News & Updates

Administering the new-generation thrombolytic reteplase within 4.5 hours of acute ischaemic stroke onset appears to be safe and as efficacious as alteplase, according to a phase II study.

Mild neurocognitive disorders (NCDs) are present in one in five community-dwelling older adults in Hong Kong, while 70 percent of older adults living in residential care homes have dementia, researchers from the Chinese University of Hong Kong (CUHK) have reported.

Apathy may have a significant impact on cognitive health of stroke survivors, according to results of a cross-sectional study by the Chinese University of Hong Kong.

An intranasally administered recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life (neuroEPO) restores cognitive function or delays progression in most patients with mild-to-moderate Alzheimer’s disease, results of the phase II/III double-blind, placebo-controlled ATHENEA trial have shown.